Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 2/2012

01-04-2012 | Original article

CD83+ dendritic cells and Foxp3+ regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer

Authors: Seigo Kashimura, Zenichiro Saze, Masanori Terashima, Nobutoshi Soeta, Satoshi Ohtani, Fumihiko Osuka, Michihiko Kogure, Mitsukazu Gotoh

Published in: Gastric Cancer | Issue 2/2012

Login to get access

Abstract

Background

Dendritic cells (DCs) are potent antigen-presenting cells that are central to the regulation, maturation, and maintenance of the cellular immune response against cancer. In contrast, CD4+CD25+ regulatory T cells (Tregs) play a central role in self-tolerance and suppress antitumor immunity. In this study, we investigated the clinical significance of mature CD83+ DCs and Foxp3+ Tregs in the primary tumor and regional lymph nodes from the viewpoint of the two opposing players in the immune responses.

Methods

We investigated, immunohistochemically, the density of CD83+ DCs and Foxp3+ Tregs in primary lesions of gastric cancer (n = 123), as well as in regional lymph nodes with (n = 40) or without metastasis (n = 40).

Results

Decreased density of CD83+ DCs and increased density of Foxp3+ Tregs were observed in the primary tumor and metastatic lymph nodes. Density was significantly correlated with certain clinicopathological features. Poor prognosis was observed in patients with a low density of CD83+ DCs and a high density of Foxp3+ Tregs in primary lesions. For patients with metastatic lymph nodes, the density of CD83+ DCs in negative lymph nodes was found to be an independent prognostic factor by multivariate analysis.

Conclusion

The density of CD83+ DCs and Foxp3+ Tregs was inversely correlated with tumor progression and reflected the prognosis of gastric cancer.
Literature
1.
Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.PubMedCrossRef
2.
Zhou LJ, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol. 1992;149:735–42.PubMed
3.
Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 1995;154:3821–35.PubMed
4.
Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190:1417–25.PubMedCrossRef
5.
Zhou L, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Immunology. 1999;93:2588–92.
6.
Thurner M, Radmayr C, Ramoner R, et al. Human renal-cell carcinoma tissue contain dendritic cells. Int J Cancer. 1996;68:1–7.CrossRef
7.
Tsukayama S, Omura K, Yoshida K, Tanaka Y, Watanabe G. Prognostic value of CD83 positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer. Oncol Rep. 2005;14:369–75.PubMed
8.
Saito H, Osaki T, Murakami D, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol. 2007;95:123–8.PubMedCrossRef
9.
Naito Y, Saito K, Shibata K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491–4.PubMed
10.
Furihata M, Ono Y, Ichikawa K, Tomita S, Fujimori T, Kubota K. Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma. Oncol Rep. 2005;14:353–6.PubMed
11.
Miyagawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T. Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol. 2004;35:1392–6.PubMedCrossRef
12.
Iwamoto M, Shinohara H, Miyamoto A, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer. 2003;104:92–7.PubMedCrossRef
13.
Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285–94.PubMedCrossRef
14.
Ng WF, Duggan PJ, Ponchel F, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood. 2001;98:2736–44.PubMedCrossRef
15.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). J Immunol. 1995;155:1151–64.PubMed
16.
Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.PubMedCrossRef
17.
Dejaco C, Dultner C, Grubeck B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology. 2005;117:289–300.CrossRef
18.
19.
Viehl C, Moore T, Liyanaga U, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2005;13:1252–8.CrossRef
20.
Rudge G, Barrett SP, Scott B, Driel IR. Infiltration of a mesothelioma by IFN-γ-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol. 2007;178:4089–96.PubMed
21.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cells development by the transcription factor Foxp3. Science. 2003;299:1057–61.PubMedCrossRef
22.
Fontenot JD, Gavin MA, Rudensky A. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;10:1330–6.
23.
Fontenot JD, Rasmussen JP, Williams M, Dooley L, Farr AG, Rudensky Y, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.PubMedCrossRef
24.
Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4+CD25+T cells in tumors from patients with early-stage non-small cell lung cancer and last-stage ovarian cancer. Cancer Res. 2001;61:4766–72.PubMed
25.
Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating C+ T cells subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465–72.PubMedCrossRef
26.
Wolf D, Wolf A, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326–31.PubMedCrossRef
27.
Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13:902–11.PubMedCrossRef
28.
Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423–34.PubMedCrossRef
29.
Mizukami Y, Kono K, Kawaguchi Y, et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer. 2008;98:148–53.PubMedCrossRef
30.
Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13:2075–81.PubMedCrossRef
31.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef
32.
Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer. 1990;66:2012–6.PubMedCrossRef
33.
Dadabayev A, Sandel M, Menon A, et al. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother. 2004;53:978–86.PubMedCrossRef
34.
Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Ley/Leb antigen with survival in patients with carcinoma of the lung. N Engl J Med. 1992;327:14–8.PubMedCrossRef
35.
Matsuda H, Mori M, Tsujitani S, Ohno S, Kuwano H, Sugimachi K. Immunohistochemical evaluation of squamous cell carcinoma antigen and S-100 protein-positive cells in human malignant esophageal tissues. Cancer. 1990;65:2261–5.PubMedCrossRef
36.
Schwaab T, Weiss JE, Schned AR, Barth RJ Jr. Dendritic cell infiltration in colon cancer. J Immunother. 2001;24:130–7.CrossRef
37.
Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4(+)CD25 high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Oncol. 2005;124:151–7.
38.
Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–54.PubMedCrossRef
39.
Sarrs M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity. 2008;28:402–13.CrossRef
40.
Terme M, Chaput N, Combadiere B, Ma A, Ohteki T, Zitvogel L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol. 2008;180:4679–86.PubMed
41.
Fehervari A, Sakaguchi S. Control of Foxp3+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol. 2004;16:1769–80.PubMedCrossRef
42.
Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27:145–59.PubMedCrossRef
43.
Schmidt J, Eisold S, Büchler MW, Märten A. Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother. 2004;53:1018–26.PubMedCrossRef
44.
Van Meirvenne S, Dullaers M, Heirman C, Straetman L, Michiels A, Thielemans K. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells. Mol Ther. 2005;12:922–32.PubMedCrossRef
Metadata
Title
CD83+ dendritic cells and Foxp3+ regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer
Authors
Seigo Kashimura
Zenichiro Saze
Masanori Terashima
Nobutoshi Soeta
Satoshi Ohtani
Fumihiko Osuka
Michihiko Kogure
Mitsukazu Gotoh
Publication date
01-04-2012
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 2/2012
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-011-0090-9

Other articles of this Issue 2/2012

Gastric Cancer 2/2012 Go to the issue

Case report

Adenocarcinoma arising in an intramural diverticulum presenting as a long-standing submucosal tumor

Original article

Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer

Case report

A case of lymph node metastasis following a curative endoscopic submucosal dissection of an early gastric cancer

Original article

A comparison of postoperative quality of life and dysfunction after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: results from a multi-institutional RCT

Original article

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

Original article

Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits